|3 Months Ended|
Mar. 31, 2021
|Risks and Uncertainties [Abstract]|
Note 11 – Concentrations.
During the three months ended March 31, 2021, we had one significant customer, which accounted for 31% of sales.
We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.
At March 31, 2021, we had one customer which accounted for 61% of our account receivable balances.
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef